---
title: "FDA, EMA and Infarmed GMP Guidance and Warning Letters"
description: "GMP guidance and warning letters from FDA, EMA, EudraLex and Infarmed, with document dates, source links and change-comparison fields. The published dataset contains 416 document records."
url: "https://www.jsonify.com/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9"
---

# FDA, EMA and Infarmed GMP Guidance and Warning Letters

GMP guidance and warning letters from FDA, EMA, EudraLex and Infarmed, with document dates, source links and change-comparison fields. The published dataset contains 416 document records.

## About this dataset

Official GMP regulatory documents with source links, document references, source-stated dates and revisions, capture timestamps and document change tracking. Refreshed 19 November 2026 with 416 document records.

## What you can use it for

Researchers can compare document records using content hashes and change fields. Regulatory teams can find documents by agency, date, document type or product area. Analysts can review warning-letter categories and document source links.

## Coverage

FDA: 235 warning letters, 11 draft guidance documents and 11 final guidance documents. EMA: 6 GMP/GDP guidance documents. EudraLex: 38 Volume 4 references. Infarmed: 47 recall circulars, 10 GMP/GDP quality circulars and 8 restriction-lifted circulars. EudraGMDP: 50 public GMP non-compliance reports. Publication dates span August 2008 to 18 November 2026, including older current reference documents. Recent regulatory records use a rolling two-year discovery window; this is a scoped sample, not an exhaustive regulatory archive.

## Sources

ec.europa.eu, ema.europa.eu, eudragmdp.ema.europa.eu, extranet.infarmed.pt, fda.gov, health.ec.europa.eu, infarmed.pt

## Column explanations

source_url links to the official document page; document_pdf_url links to its PDF when available. document_id is the source reference; revision_number, publication_date and last_modified_date contain only source-stated values. first_seen_at preserves the earliest recorded observation; captured_at identifies this collection. content_hash fingerprints complete PDF bytes or normalized HTML text, as specified in content_hash_basis. change_type is new, revised or unchanged compared with the previous saved snapshot; unknown denotes an unavailable document. unavailable_document explicitly flags a failed document retrieval. Blank hashes are not evidence of unchanged content. change_basis and source_date_notes explain baseline and date limitations. agency, issuing_office, document_type, title, company, product_area and summary_or_violation_category describe each record.

## Limitations

Fourteen documents were unavailable at capture: 13 FDA warning letters and one Infarmed notice. They retain verified official metadata and source links, with blank hashes, unavailable_document=true and change_type=unknown. The 402 available documents establish the initial hash baseline; new means new to the hash baseline, not necessarily newly published. Later successful refreshes compare full-document hashes against the previous saved snapshot. Source dates and revision numbers remain blank where not stated. PDF hashes cover document bytes; HTML hashes cover normalized document text. This refresh reused the complete official index captured earlier on 19 November 2026 and retrieved document contents again. Refreshes are manual; no automatic schedule is enabled.

## Licence

Get this sample data, free: CC BY 4.0. Use it for anything, including commercially, with credit to Jsonify. Credit it as: Data: Jsonify, CC BY 4.0, https://www.jsonify.com/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9
https://creativecommons.org/licenses/by/4.0/

Or buy the full dataset: the complete current dataset as a one-off export under a commercial licence, priced per dataset; book a call for a quote (https://calendly.com/paulhunkin/30min).

Or collect your own: run this pipeline in your own Jsonify account, or book a live feed for your team (https://calendly.com/paulhunkin/30min). Data you collect is yours to use under your Jsonify terms (https://www.jsonify.com/legal/terms#delivered-dataset), with no credit line.

## Frequently asked questions

**Is this sample data free to use?**
Yes. The sample on this page is published under CC BY 4.0. You can use it in your own work, products and research, including commercially, as long as you credit Jsonify.

**How do I credit Jsonify?**
Put this line wherever you show or publish the data, and say if you changed it: Data: Jsonify, CC BY 4.0, https://www.jsonify.com/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9

**Can I buy the full dataset?**
Yes. The complete current dataset, with its history on request, is available as a one-off export under a commercial licence: no credit line, yours to use in products and research. It is priced per dataset. Book a call for a quote.

**How is that different from collecting my own?**
The free sample is a slice of the data Jsonify collected, as of the date shown on this page. If you run the pipeline in your own Jsonify account, or have us run a live feed for you, the data you collect is yours to use under your Jsonify terms. It needs no credit line, and it stays current on your schedule.

**What do Download and Customize do?**
Both open a free Jsonify workspace of your own. Download puts this sample data in it, ready to export as CSV or JSON. Customize puts a copy of the pipeline in it, so you can change the sources, the rows it collects or the schedule.

**Does collecting my own cost anything?**
Your account includes free rows to start. Past that you pay for the rows you collect, as set out on the pricing page. Nothing is charged for the Download or Customize step itself.

**What does a live feed for my team include?**
Jsonify runs the pipeline for you on a schedule, sends change alerts, keeps the history, and adds the coverage you need. It is priced per team. Book a demo to scope it.

**I run a site this data was read from. What can I do?**
Jsonify reads public pages and credits each source. If something on this page should not be here, or you want your site left out of future runs, tell us and we will act on it. [Report a problem or request removal](https://www.jsonify.com/legal/site-owners).

Refresh: On-demand; no schedule enabled.

- Active pipeline version: v4
- Schedule: none
- Pipeline updated: 20 Nov 2026
- Directory ID: 8099814fc1b9
- HTML page: https://www.jsonify.com/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9

- Sample files (CSV, JSON, schema): https://github.com/jsonifyco/public-datasets/tree/main/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9

## Pipeline steps

1. **Verified Index** (Input): Optional verified official document index from an interrupted refresh. Omit for normal live discovery; use an exact captured dataset revision for recovery.
2. **Previous** (Input): Last published regulatory snapshot, used only for identity, first-seen dates and change comparisons.
3. **Sources** (Sources): europa.eu, fda.gov, infarmed.pt
4. **Sources** (Step): Prepare official regulatory sources and read the previous published snapshot for change comparisons.
5. **Discover** (Map): Discover current documents in FDA, EMA, European Commission and Infarmed official indexes.
6. **Organize** (Step): Deduplicate document identities and interleave source families so bounded runs include balanced source coverage.
7. **Extract documents** (Map): Retrieve documents or retain verified index metadata with explicit unavailable status when the document cannot be acquired.
8. **Changes** (Step): Compare full document fingerprints with the last successfully published snapshot and retain original first-seen dates.
9. **Main** (Output): Current official GMP regulatory documents with source traceability and changes since the last published snapshot.

## Outputs

- **FDA, EMA and Infarmed GMP Guidance and Warning Letters**: main (416 rows); revision 3, published 20 Nov 2026. Official GMP regulatory sample refreshed 19 November 2026: 416 records covering FDA warning letters and guidance, EMA GMP/GDP guidance, EudraLex Volume 4 references, Infarmed circulars and EudraGMDP non-compliance reports. Source-stated publication dates span August 2008 to 18 November 2026, including older current references. Includes canonical source links, document references, source-stated revisions and dates, capture timestamps and change tracking. 402 available documents have content hashes; 14 unavailable documents retain verified metadata with blank hashes and unknown change status. This refresh establishes the first hash baseline; new does not mean newly issued. Refreshes are manual; no schedule is enabled.

## Preview: FDA, EMA and Infarmed GMP Guidance and Warning Letters / main

| # | agency | captured\_at | captured\_date | change\_basis | change\_type | company | content\_hash | content\_hash\_basis | date | date\_basis | document\_id | document\_key | document\_pdf\_url | document\_type | first\_seen\_at | issuing\_office | last\_modified\_date | listing\_url | product\_area | publication\_date | revision\_number | source\_date\_notes | source\_url | summary\_or\_violation\_category | title | unavailable\_document | url |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Infarmed | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new |  | 843e736f04c01e13064d92fb00eda3246a9e59cbea4c4289ffa768c79232d2fb | SHA-256 of complete PDF bytes | 2026-11-13 | Circular issue date | 104/CD/550.20.001 | Infarmed:104/CD/550.20.001:2026 | https://www.infarmed.pt/documents/15786/12277905/Limeciclina+Atral+408+mg+Capsula%C2%A0%C2%A0+Levantamento+de+Suspensao+da+AIM/81133d51-5876-662a-b0ef-493eb21cda46?version=1.0 | Circular: restriction lifted | 2026-11-19T18:05:28.740874+00:00 | Infarmed |  | https://www.infarmed.pt/web/infarmed/circulares | Limeciclina Atral 408 mg Capsula Levantamento de Suspensao da AIM | 2026-11-18 | 1.0 | Publication date is the official index posting date; date is the circular issue date. | https://www.infarmed.pt/documents/15786/12277905/Limeciclina+Atral+408+mg+Capsula%C2%A0%C2%A0+Levantamento+de+Suspensao+da+AIM/81133d51-5876-662a-b0ef-493eb21cda46 | "Limeciclina Atral 408 mg Cápsula - Levantamento de Suspensão da AIM" | Limeciclina Atral 408 mg Capsula Levantamento de Suspensao da AIM | false | https://www.infarmed.pt/documents/15786/12277905/Limeciclina+Atral+408+mg+Capsula%C2%A0%C2%A0+Levantamento+de+Suspensao+da+AIM/81133d51-5876-662a-b0ef-493eb21cda46?version=1.0 |
| 2 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | Natural Essentials, Inc. | d22492342afddfbc8e0e0a6ff3ab6287f7ea70d3133f8cd2d37e88a90ca9bb3d | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-10 | Letter issue date | MARCS-CMS 738543; 320-27-22 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-17 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Natural Essentials, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026 |
| 3 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | Umicore Argentina S.A. | be7ed044ef54dfaab2e685c70c2c2d1d55d3cb684572d227ce45c34c8c9d6fd1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-06 | Letter issue date | MARCS-CMS 736869; 320-27-20 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | 2026-11-17 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | Umicore Argentina S.A. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026 |
| 4 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | Shenzhen Benliju Biotech Co., Ltd. | af0def15b7700768792e835078342368d6c55d2cc4eaf8fec625e75d071d0bb1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-06 | Letter issue date | MARCS-CMS 738522; 320-27-21 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shenzhen-benliju-biotech-co-ltd-738522-11062026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-17 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shenzhen-benliju-biotech-co-ltd-738522-11062026 | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | Shenzhen Benliju Biotech Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shenzhen-benliju-biotech-co-ltd-738522-11062026 |
| 5 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | Nanjing Hanxin Pharmaceutical Technology Co. Ltd. | 4a47f6fe5763d608d3663b83ab2ae19e7cec60d396330f295b925619d9bcc398 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-03 | Letter issue date | MARCS-CMS 734913; 320-27-19 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-10 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | Request for Records/CGMP/API/Adulterated | 2026-11-10 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026 | Request for Records/CGMP/API/Adulterated | Nanjing Hanxin Pharmaceutical Technology Co. Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026 |
| 6 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | USV Private Limited | 9b7cbe7a859f3d2104429fcf896257494f4f3542f89efbf671ef8e0fa7bd3886 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-02 | Letter issue date | MARCS-CMS 735938; 320-27-17 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-10 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-11-10 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026 | CGMP/Finished Pharmaceuticals/Adulterated | USV Private Limited - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026 |
| 7 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | LGM Pharma Solutions, LLC | 14d8f50864a15dd411719912bf93b7926ed768cf176dac5648a9b20602d8ccb1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-11-02 | Letter issue date | MARCS-CMS 736085; 320-27-18 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-17 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-11-17 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026 | CGMP/Finished Pharmaceuticals/Adulterated | LGM Pharma Solutions, LLC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026 |
| 8 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new |  | 336760c2b75c7e9d533e7287dcabe87c17d0991431d57d7e0edc165d05ee2793 | SHA-256 of complete PDF bytes | 2026-11-02 | Guidance issue date | FDA-2023-D-4299 | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products | https://www.fda.gov/media/196183/download | Guidance (final) | 2026-11-09 | Center for Biologics Evaluation and Research | 2026-11-02 | https://www.fda.gov/regulatory-information/search-fda-guidance-documents | Gene Therapy | 2026-11-02 |  |  | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products | Final guidance; Gene Therapy | Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products | false | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products |
| 9 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Conroe Welding Supply, Inc. | 4ecc729857b41ff664865433d884c2ea072368ebbf99031296e3b7d1cf9ad594 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-29 | Letter issue date | MARCS-CMS 731507; 320-27-16 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Medical Gases/Adulterated | 2026-11-03 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026 | CGMP/Medical Gases/Adulterated | Conroe Welding Supply, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026 |
| 10 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | Chongqing Qiancan Technology Co., Ltd. | 0d66f22f0e6c01c926a88cef7a523db194c547033a5ec24ff832372ac74d8cec | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-29 | Letter issue date | MARCS-CMS 736416; 320-27-14 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-qiancan-technology-co-ltd-736416-10292026 |  | Warning letter | 2026-11-19T18:05:28.740874+00:00 | Center for Drug Evaluation and Research (CDER) | 2026-11-10 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | 2026-11-10 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-qiancan-technology-co-ltd-736416-10292026 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | Chongqing Qiancan Technology Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-qiancan-technology-co-ltd-736416-10292026 |
| 11 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Pritam International Private Limited | 9e9cdb3849dc53058b67ec8ad4f5bfea6755550494e4a3c3b1388d18d8accdeb | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-27 | Letter issue date | MARCS-CMS 738079; 320-27-12 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-11-03 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026 | CGMP/Finished Pharmaceuticals/Adulterated | Pritam International Private Limited - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026 |
| 12 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Guangzhou Jiugong Research And Development Biotechnology Co., Ltd. | 9b99374ca254dd2a0192c2fd7fdc4d51dda59e403196f2b65a5d2474747d872a | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-27 | Letter issue date | MARCS-CMS 737769; 320-27-13 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-03 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Guangzhou Jiugong Research And Development Biotechnology Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026 |
| 13 | Infarmed | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new |  | 701b016c2a1cb2cb3b774a10565309be0d93c2c74aafdb7f3d7e44c162914ff7 | SHA-256 of complete PDF bytes | 2026-10-26 | Circular issue date | 097/CD/550.20.001 | Infarmed:097/CD/550.20.001:2026 | https://www.infarmed.pt/documents/15786/12277901/Recolha+do+medicamento+Besilato+de+Atrac%C3%BArio+Basi%2C+10+mg+ml%2C+Solu%C3%A7%C3%A3o+injet%C3%A1vel+-+lote+n.%C2%BA+P0092%2C+validade+01+2027/54c59033-abcb-beb4-a2b8-cfa5054e32cb?version=1.0 | Recall circular | 2026-11-09 | Infarmed |  | https://www.infarmed.pt/web/infarmed/circulares | Recolha do medicamento Besilato de Atracúrio Basi, 10 mg ml, Solução injetável - lote n.º P0092, validade 01 2027 | 2026-11-04 | 1.0 | Publication date is the official index posting date; date is the circular issue date. | https://www.infarmed.pt/documents/15786/12277901/Recolha+do+medicamento+Besilato+de+Atrac%C3%BArio+Basi%2C+10+mg+ml%2C+Solu%C3%A7%C3%A3o+injet%C3%A1vel+-+lote+n.%C2%BA+P0092%2C+validade+01+2027/54c59033-abcb-beb4-a2b8-cfa5054e32cb | por ter sido detetado potencial contaminação e contaminação cruzada. | Recolha do medicamento Besilato de Atracúrio Basi, 10 mg ml, Solução injetável - lote n.º P0092, validade 01 2027 | false | https://www.infarmed.pt/documents/15786/12277901/Recolha+do+medicamento+Besilato+de+Atrac%C3%BArio+Basi%2C+10+mg+ml%2C+Solu%C3%A7%C3%A3o+injet%C3%A1vel+-+lote+n.%C2%BA+P0092%2C+validade+01+2027/54c59033-abcb-beb4-a2b8-cfa5054e32cb?version=1.0 |
| 14 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Guangdong Bangze Medicine Co., Ltd. | 25acc1a90178ad0b4406456826cb93791bc3bd126c58a2585f706f21a14bff56 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-26 | Letter issue date | MARCS-CMS 734509; 320-27-10 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-11-03 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-11-03 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Guangdong Bangze Medicine Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026 |
| 15 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | TSP Solutions Pte. Ltd. | f83dc2813a5dc790bfd721e38f102bab2f75e66c26666f6ec344cbaffea38cc2 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-22 | Letter issue date | MARCS-CMS 735071; 320-27-07 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-27 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-10-27 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026 | Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC | TSP Solutions Pte. Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026 |
| 16 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Sanrace Biotechnology Co., Ltd. | 70b35f2a5df9dadd55362c72293475acdf70133eb034d2cfcad117d6836320e3 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-22 | Letter issue date | MARCS-CMS 737549; 320-27-09 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-27 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-27 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026 | CGMP/Finished Pharmaceuticals/Adulterated | Sanrace Biotechnology Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026 |
| 17 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Northland Nuclear Medicine, LLC | e81fed15b67a6d7062241bb691916b5aaf6e101034ea62c63e29d59436c986db | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-22 | Letter issue date | MARCS-CMS 736893; 320-27-08 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-27 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-27 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026 | CGMP/Finished Pharmaceuticals/Adulterated | Northland Nuclear Medicine, LLC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026 |
| 18 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Bausch & Lomb Inc.  | 6e0a2c824803440e26d3d0d8738582945bdc62dc74e5b4d2917476910c63ba87 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-04 | Letter issue date | MARCS-CMS 732398; 320-26-123 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-15 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-15 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026 | CGMP/Finished Pharmaceuticals/Adulterated | Bausch & Lomb Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026 |
| 19 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Glukem Biocare Private Limited | 5c641ff22fe5539a2e9baa1157b2de76bbece01801d70db242ec8529df333ac8 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-16 | Report issue date | MT/004NCR/2026 | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188112 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Malta Medicines Authority |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.2 Non-sterile products 1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.17 Other: Manufacture of intermediates (pellets)(en) 1.6 Quality control testing 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical | 2026-10-16 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188112 | The inspection resulted in a critical deficiency related to contamination risk in the Fluid Bed Coating (FBC) equipment due to an observed pool of liquid and residue in a section of the inlet air plenum of a fully cleaned FBC. The flaws were due to common design between FBCs (inclination of plenum n | MT/004NCR/2026 - Glukem Biocare Private Limited | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188112 |
| 20 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Rohto Pharmaceutical Co., Ltd. | 73ce1ceb50da453ec2cff67b2bfd194bf1f0eed36ac4c54bbb8085fd030fa510 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-14 | Letter issue date | MARCS-CMS 733215; 320-27-06 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated/OTC | 2026-10-20 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026 | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated/OTC | Rohto Pharmaceutical Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026 |
| 21 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new |  | ec163d276b071f94604724d9fa362f0b13f7bb266b02eb46526683c87a7a329a | SHA-256 of complete PDF bytes | 2026-10-09 | Guidance issue date | FDA-2024-D-2581 | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and | https://www.fda.gov/media/180206/download | Guidance (final) | 2026-11-09 | Center for Drug Evaluation and Research | 2026-10-13 | https://www.fda.gov/regulatory-information/search-fda-guidance-documents | Biosimilars | 2026-10-09 |  |  | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and | Final guidance; Biosimilars | Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers | false | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-and |
| 22 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | First observation of this document | new | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 61a5e2c6a1d42787fa249fe907248f53609ac715cd28c07fbb336d6cbe9b0945 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-08 | Report issue date | NL/H 26/2008484B | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188001 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-19T18:05:28.740874+00:00 | Health And Youth Care Inspectorate |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2 Lyophilisates 1.1.1.4 Small volume liquids 1.1.1.6 Other: cell therapy products and gene therapy products(en) 1.2 Non-sterile products 1.2.1 Non-sterile products (processing operations for  | 2026-10-08 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188001 | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human | NL/H 26/2008484B - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188001 |
| 23 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 7f05863b911dbbce73e2a3f67638c5ffb5285c28e7e439a601e4d32649d7c719 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-07 | Report issue date | NL/H 26/2008484D | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187964 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Health And Youth Care Inspectorate |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.6 Other: cell therapy products and gene therapy products(en) 1.1.3 Batch certification 1.2 Non-sterile products 1.2.2 Batch certification 1.3 Biological medicinal products (list of product ty | 2026-10-07 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187964 | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human | NL/H 26/2008484D - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187964 |
| 24 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 21d12a7e6d07b27146b8d74c7c648cbe1b1c71fc5ad7daedefe5080ac5aa62ca | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-07 | Report issue date | NL/H 26/2008484C | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187963 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Health And Youth Care Inspectorate |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.1 Sterile products 1.1.3 Batch certification 1.2 Non-sterile products 1.2.2 Batch certification 1.6 Quality control testing 1.6.1 Microbiological: sterility 1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical 1.6.4 Biological Clarifying remarks (for public users): ad 1.1.3 and 1.2.2: Batc | 2026-10-07 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187963 | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human | NL/H 26/2008484C - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187963 |
| 25 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 0c7884ef52dfa4396f7e7bdbd22121c9526f636133ce213cf734fbbbf38fbb91 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-07 | Report issue date | NL/H 26/2008484A | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187962 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Health And Youth Care Inspectorate |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2 Lyophilisates 1.2 Non-sterile products 1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.8 Other solid dosage forms 1.5 Packaging 1.5.1 Primary Packagi | 2026-10-07 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187962 | The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human | NL/H 26/2008484A - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187962 |
| 26 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Eurofins SF Analytical Laboratories, Inc. | 576b4707da31402ebd35a1fdee9b423f307a128c6434bbb534ed82be4be4f0a6 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-06 | Letter issue date | MARCS-CMS 736056; 320-27-05 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-13 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026 | CGMP/Finished Pharmaceuticals/Adulterated | Eurofins SF Analytical Laboratories, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026 |
| 27 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Silgan Dispensing Systems | 8ea2906f44040f50280456f74d265ef8d92a30c3dd4e18ad46f0e3b15093b8fa | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-05 | Letter issue date | MARCS-CMS 734538; 320-27-04 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/OTC | 2026-10-13 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026 | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/OTC | Silgan Dispensing Systems - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026 |
| 28 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Hanlim Pharm Co., Ltd. | 3fb0d9b6514ad99c40ad712eb45d2bb052621d72ec1dae9724420771b108d513 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-02 | Letter issue date | MARCS-CMS 734782; 320-27-03 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-13 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026 | CGMP/Finished Pharmaceuticals/Adulterated | Hanlim Pharm Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026 |
| 29 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Zhejiang Gaorong Cosmetic Co., Ltd. | d5e34296fc9dbac5fcc6e439a663a2127fae21592079332254ea0b227cb48387 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-01 | Letter issue date | MARCS-CMS 732511; 320-27-01 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026 | CGMP/Finished Pharmaceuticals/Adulterated | Zhejiang Gaorong Cosmetic Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026 |
| 30 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Signature Formulations LLC | 31172b18651386d85ce560295d8b7a303f640ea509a172699824c9df962a8528 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-10-01 | Letter issue date | MARCS-CMS 737964; 320-27-02 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026 | CGMP/Finished Pharmaceuticals/Adulterated | Signature Formulations LLC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026 |
| 31 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Baxter International Inc. | 3d8ba70c46fdf22b5211ab4a7aff10be676bfb613584beb6a37a033a2b8e8187 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-29 | Letter issue date | MARCS-CMS 733231; 320-26-132 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026 | CGMP/Finished Pharmaceuticals/Adulterated | Baxter International Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026 |
| 32 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | SnugZ USA, Inc.  | af261fc4a26df5dbc6c04d9dc60c493223acb0aaeec6963d66829c75a443ecd4 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-28 | Letter issue date | MARCS-CMS 735284; 320-26-131 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-20 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-20 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026 | CGMP/Finished Pharmaceuticals/Adulterated | SnugZ USA, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026 |
| 33 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Ocb Pharmaceutical S.R.L. | c40897cf2bcd5215e2f245a71be0b99b155d07c2a86c55c007f51c54a816a263 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-28 | Report issue date | NCF-II/NC2026/01/CAT | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187807 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Spanish Agency Of Medicines And Medical Devices |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.4 Other products or manufacturing activity 1.4.1 Manufacture of 1.4.1.3 Other: Manufacturing of active substances(en) Manufacture of active substance. Names of substances subject to non-compliant: BISMUTH CITRATE(en) [2187WR]BISMUTH SUBCITRATE COLLOIDAL(en) [90105A]BISMUTH SUBGALLATE(en) [90773A]B | 2026-09-28 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187807 | During the inspection, a total of nine (9) deficiencies were identified, one (1) of them were classified as critical and eight (8) as major. The deficiencies identified demonstrate significant weakness in the pharmaceutical quality system implemented at the site and raise serious concerns regarding  | NCF-II/NC2026/01/CAT - Ocb Pharmaceutical S.R.L. | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187807 |
| 34 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Jiangmen Shuizirun Sanitary Articles Co., Ltd.  | 64f65f7a58759f493878cf8643093fcdd73c4b675271af17ed42ae98155e2303 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-23 | Letter issue date | MARCS-CMS 722974; 320-26-130 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated/OTC | 2026-10-13 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026 | CGMP/Finished Pharmaceuticals/Adulterated/OTC | Jiangmen Shuizirun Sanitary Articles Co., Ltd. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026 |
| 35 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new |  Fresenius Kabi USA LLC | 2e5048b6b3ca078fae32ff37e632d2dd23b1762816d94f86fd7999cc354e72ec | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-22 | Letter issue date | MARCS-CMS 733107; 320-26-129 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-29 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026 | CGMP/Finished Pharmaceuticals/Adulterated | Fresenius Kabi USA LLC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026 |
| 36 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Babikian Healthcare Products CJSC | e079bcb87445474e6d2ec3e358c0cc8c2f25e57dfc324710efa7d7348bb77d43 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-21 | Letter issue date | MARCS-CMS 730513; 320-26-128 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-29 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026 | CGMP/Finished Pharmaceuticals/Adulterated | Babikian Healthcare Products CJSC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026 |
| 37 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Xi'an Guokang Ruijin Pharmaceutical Co. Ltd. | 61e283eacfb05bf69ca1014ed74712fbd5d6f1a39df14990423ef1abb1ce6d6d | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-21 | Report issue date | FIMEA/2026/003795 | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187670 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Finnish Medicines Agency |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.4 Other products or manufacturing activity 1.4.1 Manufacture of 1.4.1.3 Other: active substance(en) Manufacture of active substance. Names of substances subject to non-compliant: DEXAMETHASONE SODIUM PHOSPHATE(en) BETAMETHASONE(en) DEXAMETHASONE(en) 3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTI | 2026-09-21 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187670 | The inspection team identified 18 deficiencies (grouped) against EU GMP, of which 11 were classified as Major. The major deficiencies were related to: - Inadequacy of Quality Assurance oversight and Quality management system - Inadequate design, poor maintenance/cleaning, lack of contamination contr | FIMEA/2026/003795 - Xi'an Guokang Ruijin Pharmaceutical Co. Ltd. | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187670 |
| 38 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Empower Clinic Services, LLC dba Empower Pharmacy | 1a6a9e08e65bebfd99712884f3e6fe1bc24d4f2aa1cb83d6c7517fbdee96140c | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-18 | Letter issue date | MARCS-CMS 738238 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-22 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | 2026-09-22 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026 | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Empower Clinic Services, LLC dba Empower Pharmacy - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026 |
| 39 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Curia New York, Inc.  | f6f9277a66dbd51c6968387a96ebdd01887a1a5a002f99f11865e38a1a5f2105 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-18 | Letter issue date | MARCS-CMS 728790; 320-26-127 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curia-new-york-inc-728790-09182026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | 2026-09-29 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curia-new-york-inc-728790-09182026 | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated | Curia New York, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curia-new-york-inc-728790-09182026 |
| 40 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Bentley Laboratories LLC | 89ba8bef67a1798f9e446ba49faab0c97eea62f64c5e08d773abf5347eab9b74 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-17 | Letter issue date | MARCS-CMS 732028; 320-26-126 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-29 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated | 2026-09-29 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026 | CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated | Bentley Laboratories LLC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026 |
| 41 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new |  | bd4f2c82ea379c463e3cd034535699654d000191a302bf2723e695c57186ad14 | SHA-256 of complete PDF bytes | 2026-09-16 | Guidance issue date | FDA-2024-D-2732 | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood | https://www.fda.gov/media/182751/download | Guidance (final) | 2026-11-09 | Center for Biologics Evaluation and Research | 2026-09-17 | https://www.fda.gov/regulatory-information/search-fda-guidance-documents | Blood, Blood Products | 2026-09-16 |  |  | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood | Final guidance; Blood, Blood Products | Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method | false | https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-blood |
| 42 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | SCA Pharmaceuticals, LLC | e4bebf91f0bb4853fd726bbcb2727a4744c9957e7df5d6c5a96ceb216f129076 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-14 | Letter issue date | MARCS-CMS 724202 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-13 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-13 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026 | CGMP/Finished Pharmaceuticals/Adulterated | SCA Pharmaceuticals, LLC - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026 |
| 43 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | kdc/one Chatsworth, Inc. | dc3f8cee08bb2e8e1435aec5c4c92780a72543e4ba7d5a831a57be54685f796a | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-08 | Letter issue date | MARCS-CMS 733205; 320-26-124 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-22 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-22 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026 | CGMP/Finished Pharmaceuticals/Adulterated | kdc/one Chatsworth, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026 |
| 44 | EMA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new |  | 4130b578aa945eb72531eb6986978681100e28a34dfda5f8e4ccc3bf57cd851e | SHA-256 of complete PDF bytes | 2026-09-07 | Last updated date where stated; otherwise first publication |  | https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdf | https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdf | GMP/GDP guidance | 2026-11-09 | EMA | 2026-09-07 | https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/compilation-union-procedures-inspections-exchange-information | GMP / pharmaceutical manufacturing | 2024-08-01 | 3 | Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products Legal effective date: 10/09/2026 English (EN) (173.93 KB - PDF) First published: 01/08/2024 Last updated: 07/09/2026 View | https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdf | Guidance on Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products | Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products | false | https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdf |
| 45 | Infarmed | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Document unavailable; no content hash or change determination possible | unknown |  |  |  | 2026-09-04 | Circular issue date stated on official document page | 087/CD/550.20.001 | Infarmed:087/CD/550.20.001:2026 | https://www.infarmed.pt/documents/15786/12277909/Suspens%C3%A3o+de+fabrico+e+recolha+de+solu%C3%A7%C3%B5es+est%C3%A9reis+do+fabricante+Sterisets+Manufacturing%2C+SA/89087f2b-4905-d01f-207d-2fc6162b2214?version=1.0 | Recall circular | 2026-11-09 | Infarmed | 2026-11-03 | https://www.infarmed.pt/web/infarmed/circulares | Suspensão de fabrico e recolha de soluções estéreis do fabricante Sterisets Manufacturing, SA | 2026-11-03 | 1.0 | Official document page metadata verified; the attachment could not be downloaded. Document content and changes are unknown. | https://www.infarmed.pt/web/infarmed/institucional/documentacao_e_informacao/informacao-tematica?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=13774111&_101_type=document | Manufacturing suspension and recall of sterile solutions, as stated by the official notice title. Full document unavailable. | Suspensão de fabrico e recolha de soluções estéreis do fabricante Sterisets Manufacturing, SA | true | https://www.infarmed.pt/documents/15786/12277909/Suspens%C3%A3o+de+fabrico+e+recolha+de+solu%C3%A7%C3%B5es+est%C3%A9reis+do+fabricante+Sterisets+Manufacturing%2C+SA/89087f2b-4905-d01f-207d-2fc6162b2214?version=1.0 |
| 46 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | TCI Co., Ltd BioCosme PABP BRANCH | c48d2e5458ef30bbb9fea43e1035463c570bbceb885d5b6560601c840e756136 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-02 | Letter issue date | MARCS-CMS 736888; 320-26-122 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-10-06 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-10-06 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026 | CGMP/Finished Pharmaceuticals/Adulterated | TCI Co., Ltd BioCosme PABP BRANCH - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026 |
| 47 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Happy Farm Botanicals, Inc. | 24b112821657bc796aba99b576693538a393e4ff054f1edfd719c163db8c21a1 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-09-01 | Letter issue date | MARCS-CMS 731926; 320-26-121 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-08 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-08 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026 | CGMP/Finished Pharmaceuticals/Adulterated | Happy Farm Botanicals, Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026 |
| 48 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Jabil Inc. | ae8530911c10ca8c649144d06061e5470d0a3f9c42a781579b2622a82a702486 | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-08-27 | Letter issue date | MARCS-CMS 731037; 320-26-120 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-01 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-01 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026 | CGMP/Finished Pharmaceuticals/Adulterated | Jabil Inc. - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026 |
| 49 | FDA | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Fresenius Medical Care AG & Co. KGaA | 8320a869feec025ddf610f0d4236fccac464f08c195a4e0161764b5abca0983f | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-08-25 | Letter issue date | MARCS-CMS 730319; 320-26-119 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026 |  | Warning letter | 2026-11-09 | Center for Drug Evaluation and Research (CDER) | 2026-09-01 | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters | CGMP/Finished Pharmaceuticals/Adulterated | 2026-09-01 |  |  | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026 | CGMP/Finished Pharmaceuticals/Adulterated | Fresenius Medical Care AG & Co. KGaA - GMP warning letter | false | https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026 |
| 50 | EMA / EudraGMDP | 2026-11-19T18:05:28.740874+00:00 | 2026-11-19 | Initial content-hash baseline; legacy sample has no comparable hash | new | Aculife Healthcare Private Limited | b8557b3becb5e1a77744504456c09c14b15812ec07db8616b15fb1788f462cdf | SHA-256 of complete normalized document text, excluding website navigation and footer | 2026-08-24 | Report issue date | MT/003NCR/2026 | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187173 | https://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do | GMP non-compliance report | 2026-11-09 | Malta Medicines Authority |  | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do | 1.1 Sterile products 1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.4 Small volume liquids 1.1.2 Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1 Large volume liquids 1.5 Packaging 1.5.2 Secondary packaging | 2026-08-24 |  | Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date. | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187173 | The inspection resulted in a critical deficiency on inadequate cleaning validation as well as eight (8) major findings. These dealt with inadequate control of identification labels inside the manufacturing area, inadequate management of visual inspection activities, sterilized product passing throug | MT/003NCR/2026 - Aculife Healthcare Private Limited | false | https://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187173 |

Automatic sample of 50 rows from the current data: 50 of 416 rows from revision 3.

## Version history

- v1 (19 Nov 2026): Added a reusable official-source refresh with document links, references, source dates, complete-document fingerprints and change tracking.
- v2 (19 Nov 2026): Retains the unavailable Sterisets notice with verified source details, a blank content hash, unknown change status and an explicit unavailable-document flag so the other documents can refresh.
- v3 (19 Nov 2026): Improves document metadata processing so the refresh can continue after repeated processing errors.
- v4 (19 Nov 2026): Retain unavailable documents, including download timeouts, with verified metadata and unknown change status. Recover interrupted refreshes from a verified index while fetching documents again.

## Repairs

No repairs needed so far.

## Latest quality checks

- v4 (19 Nov 2026) **Issues found**: Full-table structural checks passed, but the Annex 1 document has a confirmed corrupted reference and omitted source-stated date. Source completeness remains only partially verified. — 1 table, 77 rows inspected · 1 confirmed defect

## Related datasets

- [DOT Lettings: Upcoming Highway Construction Bids Across State DOTs](https://www.jsonify.com/datasets/upcoming-us-dot-construction-lettings-556d79272f4f.md): A combined table of upcoming highway construction contracts advertised by state DOTs, with letting dates, project details and published estimates where available.
- [Building Permit Data: Eight US Cities](https://www.jsonify.com/datasets/us-building-permits-e1c447fbcc9c.md): A combined table of building permits from Chicago, New York City, Los Angeles, San Francisco, Austin, Seattle, Boston and Denver.
- [Weekly U.S. Diesel and Gas Price History](https://www.jsonify.com/datasets/weekly-us-retail-diesel-and-regular-gasoline-prices-ecf766d923b4.md): Weekly U.S. retail diesel and regular gasoline prices from the U.S.


## Related on Jsonify

- [The best data extraction tools in 2026, by job](https://www.jsonify.com/blog/best-data-extraction-tools-2026.md)
- [How Jason builds and maintains data pipelines](https://www.jsonify.com/product.md)
